Evaluation of Remote DBS Programming.

Parkinson Disease Clinical Trial

— REMOTE  

Official title:

Evaluation of a Visual-Analog Scale (VAS) for Remote DBS Programming

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05193825
• Other study ID #: Remote DBS Programming
• Status: Recruiting
• Phase: N/A
• Start date: March 22, 2022
• Est. completion date: December 1, 2024

Study information

• Verified date: June 2024
• Source: Ludwig-Maximilians - University of Munich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Deep brain stimulation (DBS) represents the treatment of choice for advanced stages of Parkinson's disease (PD). Currently, adaptive closed-loop stimulation systems that apply disease-specific biomarkers, such as local field potentials (LFPs), are being actively examined to facilitate DBS programming. However, the most suitable feedback signal, still remains to be determined. The investigators previously tested the usefulness of the patient's subjective rating on a visual analogue scale (VAS) as a potential feedback signal for DBS adjustment and found that VAS-based programming lead to similar results as our standard approach. One of the practical advantages of using VAS-based programming strategies - in addition to saving time - is the principal applicability of such an approach to a remote programming setting, although a validation of such an approach is required. Within the scope of a prospective, randomized multicenter clinical trial (the REMOTE Trial), the investigators will examine the effectiveness and safety of VAS-based remote DBS programming in PD by using a novel and recently introduced software platform (Abbott NeurosphereTM Virtual Clinic) that allows for the programming through a smartphone-based video connection with the patient. Therefore, n = 50 PD patients undergoing STN-DBS surgery will be randomized and subsequent to surgery will have their IPG settings adjusted either during regular visits at the hospital or alternatively be programmed remotely through a VAS-based approach. Prior to surgery and after a 90 days follow-up period, we will assess specific clinical (MDS-Unified Parkinson's Disease Rating Scale = UPDRS, Parkinson's Disease Questionnaire-39 sum index = PDQ-39 SI, Beck Depression Inventory = BDI, Montreal Cognitive Assessment Scale = MOCA) parameters to determine the effectivity and safety of the two different strategies on the patient outcome and to correlate it with VAS ratings and MRI data. The results will support the examination of remote-based DBS programming and evaluate the patient's subjective judgment as a valid feedback signal.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 1, 2024
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age between 35 and 80 yrs.

• Ability to communicate with the study physician and to understand the requirements of the study

• Idiopathic Parkinson's Syndrome; IPS (according to MDS-Criteria)

• Implantation of a DBS device for the stimulation of the subthalamic nucleus (STN) to treat PD.

Exclusion Criteria:

• Any inability to communicate with the study physician and to understand the requirements of the study

• Exclusion criteria of an idiopathic Parkinson's syndrome (IPS)

• Fulfills the criteria of dementia (according to the International Classification of Diseases (ICD) 10)

Related Conditions & MeSH terms

• Deep Brain Stimulation
• Parkinson Disease
• Telemedicine

Intervention

Device:
• Remote Programming
Patients in the experimental group (Group B) will have their internal pulse generators (IPGs) adjusted through a novel software that allows for remote DBS programming (NeurosphereTM Virtual Clinic)
• Standard Programming
Patients in the active comparator group (Group A) will have their internal pulse generators (IPGs) adjusted through a standard procedure at their caregivers institution.

Locations

Country	Name	City	State
Germany	Ludwig Maximilian University Hospital	Munich	Bavaria

Sponsors (6)

Lead Sponsor	Collaborator
Thomas Köglsperger	Friedrich-Alexander-Universität Erlangen-Nürnberg, Heinrich-Heine University, Duesseldorf, Universitätsklinikum Hamburg-Eppendorf, Universitätsklinikum Leipzig, University Hospital Muenster

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in UPDRS-III (Stimulation ON/Medication ON = STIM-ON/MED-ON)	Part III of the MDS-Unified Parkinson's Disease Rating Scale (Range 0-128 pts. with high values indicating a more severe disease symptoms)	Assessed at Day 90
Secondary	Change in UPDRS-I	Part I of the MDS-Parkinson's Disease Rating Scale (Range 0-52 pts. with high values indicating more severe disease symptoms)	Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Secondary	Change in UPDRS-II	Part II of the MDS-Parkinson's Disease Rating Scale (Range 0-52 pts. with high values indicating more severe disease symptoms)	Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Secondary	Change in UPDRS-IV	Part IV of the MDS-Parkinson's Disease Rating Scale (Range 0-24 pts. with high values indicating more severe disease symptoms)	Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Secondary	Change in PDQ-39-SI	Parkinson's Disease Questionnaire-39 Sum Index (Range 0-100 pts. with high values indicating more severe disease symptoms)	Assessed at day -1 and +90 (day 0 = implantation of DBS electrodes)
Secondary	Change in Patient Rating (Patient Diary)	Number of hours spent with bothersome dyskinesia or in a reduced mobility state (OFF)	Assessed on a weekly basis by the patient between day +5 and +90 (day 0 = implantation of DBS electrodes)
Secondary	Number of visits at the the hospital or remotely	Number of doctor-patient contacts either in person at the hospital (Group A) or remotely (Group B)	Assessed at day +90 (day 0 = implantation of DBS electrodes)
Secondary	Change in TEED	Total Electrical Energy Delivered by the IPG; TEED (1s) = (voltage2 × frequency × pulsewidth) / impedance (1s)	Assessed at day +5 and +90 (day 0 = implantation of DBS electrodes)